Shareholders with losses of $250,000 or more are encouraged to contact the firm.
LOS ANGELES, May 25, 2023 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 23, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired First Republic Bank (“First Republic” or the “Company”) (OTC: FRCB) securities between January 14, 2021 and March 14, 2023, inclusive (the “Class Period”).
If you suffered a loss on your First Republic investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/First-Republic-Bank/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at email@example.com to learn more about your rights.
On October 14, 2022, First Republic released its third quarter 2022 financial results, reporting a slowdown of the Company’s net interest income growth to 20.6% year-over-year and a net interest margin decrease to 2.71%. The Company explained that the decrease was due to “average funding costs increasing more rapidly than the offsetting increase in the average yields on interest-earning assets.” On this news, First Republic’s stock price fell $22.14, or 16.4%, to close at $112.59 per share on October 14, 2022, thereby injuring investors.
Then, following the collapse of SVB Financial Group (“SVB”) on March 10, 2023, First Republic investors began to question the Company’s ability to withstand the interest rate environment and remain solvent. In response, First Republic’s stock price fell $83.79, or 72.9%, to close at $31.21 per share on March 13, 2023.
Then, on March 13, 2023, several analysts downgraded their ratings of First Republic due to the risks of deposit outflows leading to increased funding costs, observing that the Company’s “funding and liquidity profile has changed and represents a ‘weakest link.’” On this news, First Republic’s stock price fell $8.47, or 21.4%, to close at $31.16 per share on March 15, 2023, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants misrepresented the strength of the Company’s balance sheet and liquidity position, while also understating the significant pressure rising interest rates posed to First Republic’s business model. Defendants also misrepresented the strength of the Company’s ability to deliver consistent results across different interest rate environments, the diversity of the Company’s deposit funding base, and the Company’s ability to generate net interest income growth and maintain stable net interest margin, and as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you purchased or otherwise acquired First Republic securities during the Class Period, you may move the Court no later than June 23, 2023 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
- Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains - June 7, 2023
- CUTERA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cutera, Inc. – CUTR - June 6, 2023
- Day One Announces Pricing of Public Offering of Common Stock - June 6, 2023